References
- Saddawi-Konefka R, O'Sullivan T, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209:1869-82; PMID:22927549
- Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science 2011; 331:1565-70 ; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
- Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122
- Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9:361-71; PMID:19343034; http://dx.doi.org/10.1038/nrc2628
- Lewis CE. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-12; PMID:16423985; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005
- O'Sullivan T, Saddawi-Konefka R, Gross E, Tran M, Mayfield SP, Ikeda H, Bui JD. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep 2014; 7:989-98; PMID:24794441; http://dx.doi.org/10.1016/j.celrep.2014.03.073
- Zou W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Publishing Group 2010; 10:248-56.
- Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of Tumor-Associated Neutrophil Phenotype by TGF-b: “N1” versus “N2” TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017
- Diefenbach A, Jensen E, Jamieson A, Raulet D. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413:165-71; PMID:11557981; http://dx.doi.org/10.1038/35093109